Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Licocoumarone SCHEMBL30220504 | 1.00 | PTPN1 (1.00) | PTPN1DYRK1AAKT1CYP19A1PDE4D | |
| SCHEMBL29391195 | 0.93 | PTPN1 (1.00) | PTPN1DYRK1AAKT1CYP19A1PDE4D | |
| SCHEMBL22704765 | 0.93 | PTPN1 (1.00) | PTPN1DYRK1AAKT1CYP19A1PDE4D | |
| Glycycoumarin SCHEMBL759406 | 0.86 | PTPN1 (0.75) | PTPN1DYRK1AAKT1CYP19A1PDE4D | |
| Glycycoumarin SCHEMBL29390258 | 0.86 | PTPN1 (0.75) | PTPN1DYRK1AAKT1CYP19A1PDE4D | |
| SCHEMBL10702910 | 0.80 | PTPN1 (0.66) | PTPN1DYRK1AAKT1PDE4DALOX5 | |
| Glycyrin SCHEMBL5327472 | 0.79 | PTPN1 (0.75) | PTPN1DYRK1AAKT1PDE4DBCHE | |
| Glycyrin SCHEMBL29388094 | 0.79 | PTPN1 (0.75) | PTPN1DYRK1AAKT1PDE4DBCHE | |
| Mulberrofuran Z SCHEMBL31237321 | 0.75 | PTPN1 (0.62) | PTPN1DYRK1ACYP19A1BCHEHIF1A | |
| SCHEMBL30637443 | 0.75 | AKT1 (1.00) | PTPN1DYRK1AAKT1CYP19A1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115901978-A | Detection method of traditional Chinese medicine composition | 山东新时代药业有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-111494231-A | Three natural components in licorice root are used as tyrosinase inhibitor and used for whitening | 宁夏厚泽生物医药科技有限公司 | 2020-08-07 | — | — | CN | claimed |
| CN-103989736-B | Anti-tumor active substance in liquorice, extraction method and application thereof | 哈尔滨医科大学 | 2017-02-22 | — | — | CN | claimed |
| CN-103989736-A | Anti-tumor active substance in liquorice, extraction method and application thereof | UNIV HARBIN MEDICAL | 2014-08-20 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-12629350-B2 | Transthyretin tetramer stabilizing agent, and preventing agent or progression suppressing agent for transthyretin amyloidosis | KANEKA CORPORATION (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-118477168-A | Traditional Chinese medicine composition and preparation for treating breast cancer and preparation method thereof | 庞钰川 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024142100-A1 | A POLYHERBAL FORMULATION FOR MANAGEMENT OF CANCER | POLISHETTY RAVISHANKAR (IN) | 2024-07-04 | — | — | WO | disclosed |
| CN-117941828-A | Preparation for relieving radioactive dry mouth and preparation method thereof | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2024-04-30 | — | — | CN | disclosed |
| CN-117322514-A | Purely natural and green organic feed and preparation method thereof | 苏忠义 | 2024-01-02 | — | — | CN | disclosed |
| CN-117205283-A | Preparation for treating scalp psoriasis and preparation method thereof | 河南中医药大学 | 2023-12-12 | — | — | CN | disclosed |
| EP-4226920-A1 | TRANSTHYRETIN TETRAMER STABILIZER AND AGENT FOR PREVENTING OR SUPPRESSING PROGRESSION OF TRANSTHYRETIN AMYLOIDOSIS | Kaneka Corporation (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20080286254-A1 | Composition comprising licorice polyphenol | KANEKA CORPORATION (JP) | 2008-11-20 | — | — | US | disclosed |
| CN-100400079-C | Extraction of antiviral immune matter for curing sexual disorder and its formulation | QUNWEI SUN (CN) | 2008-07-09 | — | — | CN | disclosed |
| US-7166311-B2 | Process for producing fat composition containing hydrophobic components of glycyrrhiza | KANEKA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| CN-1642565-A | Process for producing fat composition containing hydrophobic components of glycyrrhiza | KANEGAFUCHI CHEMICAL IND (JP) | 2005-07-20 | — | — | CN | disclosed |
| US-20050118289-A1 | Process for producing fat composition containing hydrophobic components of glycyrrhiza | KANEKA CORPORATION (JP) | 2005-06-02 | — | — | US | disclosed |
| CN-1522754-A | Extraction of antiviral immune matter for curing sexual disorder and its formulation | 孙群卫 | 2004-08-25 | — | — | CN | disclosed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | disclosed |
| CN-1238205-A | Life gene leader | WANG YUEJIN (CN) | 1999-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629350-B2 | Transthyretin tetramer stabilizing agent, and preventing agent or progression suppressing agent for transthyretin amyloidosis | TTR, APOB, ALB | PTPN1 2066/4885DYRK1A 4337/4885AKT1 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.